Cardiac Resynchronisation Therapy (CRT) Devices Market Size & Growth Forecast 2027–2036, By Segments (Product, Age, End-use), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
CRT Devices Market size was around USD 3.89 Billion in 2026 and is slated to grow at 6.25% CAGR from 2027 to 2036, exceeding USD 7.13 Billion by 2036. The industry revenue for 2027 is estimated at USD 4.1 Billion.
Get more details on this report
Request Free Sample ReportCardiac Resynchronisation Therapy (CRT) Devices Market Intelligence Snapshot
Regional Market Dynamics
- North America led in 2026, supported by advanced cardiovascular infrastructure, specialized electrophysiology services, established heart failure care pathways, and access to sophisticated cardiac therapies.
- Asia Pacific is growing fastest as cardiac care infrastructure, specialized centers, healthcare expenditure, and access to advanced heart failure therapies expand.
Segment Momentum
- CRT-defibrillators accounted for 79.67% of the market in 2026 because they combine cardiac resynchronization therapy with protection against life-threatening ventricular arrhythmias, supporting broad clinical adoption.
- CRT-pacemakers are expanding rapidly as they provide effective cardiac resynchronization for appropriate patients without requiring defibrillation, supported by advances in pacing technology and personalized treatment approaches.
Market Expansion Drivers
- Rising cardiovascular disease prevalence accelerating adoption of advanced cardiac rhythm management devices
- Aging population growth increasing demand for implantable cardiac synchronization therapies
- Favorable reimbursement frameworks supporting wider accessibility of cardiac resynchronization procedures
Leading Market Participants
- Key companies in the CRT devices market include Medtronic plc (Ireland), Abbott Laboratories (United States), Boston Scientific Corporation (United States), Biotronik SE & Co. KG (Germany), MicroPort Scientific Corporation (China), LivaNova PLC (United Kingdom), Lepu Medical Technology (China), Osypka AG (Germany)
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 3.89 Billion
- 2027 Estimated Market Size: USD 4.1 Billion
- Projected Market Size: USD 7.13 Billion by 2036
- Growth Forecast: 6.25% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: CRT-Defibrillators (Product) | 65-84 Years (Age) | Hospitals (End-use)
- Emerging Opportunity Segment: CRT-Pacemakers (Product) | Above 85 Years (Age) | Ambulatory Surgical Centers (End-use)
Market Growth Drivers and Industry Trends
Rising cardiovascular disease prevalence accelerating adoption of advanced cardiac rhythm management devices
The growing burden of cardiovascular disorders is increasing the need for advanced therapeutic interventions that improve heart function and patient outcomes. The CRT devices market growth is driven by rising demand for cardiac rhythm management technologies that help synchronize ventricular contractions in patients with heart failure and related conduction abnormalities. Healthcare providers are expanding the use of these implantable devices as part of comprehensive treatment strategies aimed at improving functional capacity, symptom management, and long-term clinical care.
Aging population growth increasing demand for implantable cardiac synchronization therapies
As the global population ages, the incidence of chronic cardiac conditions requiring long-term management continues to rise. Increasing numbers of older adults will boost the CRT devices market demand because age-related cardiovascular complications often require implantable therapies that enhance cardiac performance and support improved quality of life. Physicians are also placing greater emphasis on individualized treatment approaches that address the complex clinical needs commonly observed among elderly patients with advanced heart disease.
Favorable reimbursement frameworks supporting wider accessibility of cardiac resynchronization procedures
Supportive reimbursement policies are reducing financial barriers associated with advanced cardiac therapies and encouraging broader adoption across healthcare systems. Favorable coverage mechanisms will propel the CRT devices market growth by improving patient access to cardiac resynchronization procedures and supporting healthcare providers in delivering specialized treatment. Reimbursement support also facilitates greater integration of these therapies into standard clinical practice, enabling hospitals and cardiac centers to expand procedural availability while improving access to evidence-based cardiac care.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Rising cardiovascular disease prevalence accelerating adoption of advanced cardiac rhythm management devices | 2% | High | North America, Europe | High | Near Term |
| Aging population growth increasing demand for implantable cardiac synchronization therapies | 1.7% | High | Europe, Asia Pacific | High | Mid Term |
| Favorable reimbursement frameworks supporting wider accessibility of cardiac resynchronization procedures | 1.5% | High | North America, Europe | High | Mid Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America (Largest Region)
North America held the largest position in the cardiac resynchronisation therapy (CRT) devices market in 2026, supported by advanced cardiovascular care infrastructure, high adoption of sophisticated cardiac therapies, and strong access to specialized electrophysiology services. The region benefits from well-established clinical pathways for managing heart failure and a growing emphasis on technologies that can improve cardiac function and patient outcomes. Continued investment in healthcare facilities, physician expertise, and advanced implantable cardiac technologies further reinforces demand for CRT devices across the region.
Asia Pacific (Fastest-Growing Region)
Asia Pacific is emerging as the fastest-growing regional market as cardiovascular disease management becomes a greater healthcare priority and access to advanced cardiac therapies expands. Improvements in hospital infrastructure, increasing availability of specialized cardiac centers, and greater awareness of heart failure treatment options are supporting broader adoption of CRT procedures. In addition, expanding healthcare expenditure and efforts to strengthen access to advanced medical technologies are creating favorable conditions for CRT device penetration, particularly across developing healthcare systems.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
United States 🇺🇸
Advanced cardiac adoptionThe U.S. cardiac resynchronisation therapy devices market is shaped by strong adoption of advanced heart failure management technologies across major hospital networks. Clinicians emphasize device performance, remote monitoring capabilities, and integration with digital cardiac care platforms for improved patient management.
Germany 🇩🇪
Precision cardiac therapyGermany prioritizes CRT devices within specialized cardiology centers focusing on precision-based treatment for advanced heart failure patients. Hospitals emphasize clinical reliability, long-term device performance, and integration with structured cardiac care pathways.
Japan 🇯🇵
Aging patient managementJapan’s CRT devices market is influenced by an aging population and increasing demand for long-term heart failure management solutions. Healthcare providers focus on minimally invasive implantation techniques and devices offering stable performance with extended service life.
South Korea 🇰🇷
Hospital network expansionSouth Korea is expanding CRT device utilization through advanced hospital networks and increased access to specialized cardiac care. Medical institutions prioritize efficient implantation workflows and devices that support continuous cardiac performance monitoring.
France 🇫🇷
Structured heart failure careFrance emphasizes CRT devices within structured heart failure treatment programs supported by public healthcare systems. Clinical adoption is driven by standardized treatment protocols and demand for reliable devices compatible with long-term patient follow-up care.
Italy 🇮🇹
Cardiac treatment specializationItaly’s CRT devices market is supported by specialized cardiac treatment centers focusing on managing chronic heart failure cases. Hospitals prioritize clinically validated devices and improved patient outcomes through optimized resynchronization therapy strategies.
Segment Leadership and Growth Trends
Cardiac Resynchronisation Therapy (CRT) Devices Market Share (%), by Product, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportProduct Segment Analysis: CRT-Defibrillators (Largest Segment) vs CRT-Pacemakers (Fastest-Growing Segment)
The CRT devices market was led by the CRT-defibrillators segment, which accounted for a 79.67% share in 2026. The strong position of this segment is supported by its dual capability of delivering cardiac resynchronization therapy while providing protection against life-threatening ventricular arrhythmias through defibrillation. Physicians often prefer these devices for patients with heart failure who are considered to have an elevated risk of sudden cardiac death, contributing to their widespread clinical adoption. Continuous technological improvements and broader incorporation into treatment guidelines have further reinforced their market leadership.
CRT-pacemakers represent the fastest-growing product segment as healthcare providers increasingly recognize their suitability for patients requiring cardiac resynchronization without the need for implantable defibrillation. Their adoption is expanding among carefully selected patient populations because they provide effective rhythm management while reducing device complexity. Advances in pacing technologies, improved patient selection, and growing awareness of personalized cardiac care are supporting continued growth within this segment.
Age Segment Analysis: 65-84 Years (Largest Segment) vs Above 85 Years (Fastest-Growing Segment)
Individuals aged 65–84 years dominated the CRT devices market, holding a 59.68% share in 2026. This age group represents a substantial proportion of patients affected by heart failure and cardiac conduction disorders, making them primary candidates for cardiac resynchronization therapy. Greater disease awareness, established clinical management pathways, and increasing access to specialized cardiovascular care have contributed to the extensive use of CRT devices among this population.
The above 85 years segment is emerging as the fastest-growing age category due to increasing life expectancy and the growing number of elderly patients receiving advanced cardiovascular interventions. Improvements in procedural safety, comprehensive geriatric assessment, and individualized treatment approaches are enabling clinicians to consider CRT therapy for older patients who can benefit from improved cardiac function and quality of life.
End-use Segment Analysis: Hospitals (Largest Segment) vs Ambulatory Surgical Centers (Fastest-Growing Segment)
Hospitals held the largest share in 2026 within the end-use segment because they possess the specialized infrastructure, experienced electrophysiology teams, and comprehensive diagnostic capabilities required for CRT implantation and long-term patient management. These facilities also manage complex cardiovascular cases and provide multidisciplinary care, making them the preferred setting for advanced cardiac device procedures.
The CRT devices market is experiencing rapid growth in ambulatory surgical centers as healthcare systems increasingly emphasize cost-effective and efficient delivery of specialized procedures. Technological advancements, improvements in minimally invasive implantation techniques, and growing confidence in outpatient cardiac interventions are encouraging a greater number of eligible CRT procedures to be performed in these settings while maintaining high standards of patient care.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Product | CRT-Pacemakers, CRT-Defibrillators | CRT-Defibrillators | CRT-Pacemakers |
| Age | Below 44 Years, 45-64 Years, 65-84 Years, Above 85 Years | 65-84 Years | Above 85 Years |
| End-use | Hospitals, Cardiac Care Centers, Ambulatory Surgical Centers | Hospitals | Ambulatory Surgical Centers |
Competitive Landscape and Market Positioning
Top players in the cardiac resynchronisation therapy (CRT) devices market:
- Medtronic plc (Ireland)
- Abbott Laboratories (United States)
- Boston Scientific Corporation (United States)
- Biotronik SE & Co. KG (Germany)
- MicroPort Scientific Corporation (China)
- LivaNova PLC (United Kingdom)
- Lepu Medical Technology (China)
- Osypka AG (Germany)
Innovation continues to redefine competitive priorities as manufacturers focus on improving device performance, procedural efficiency, and long-term patient management rather than competing solely on established product portfolios. Greater emphasis on device connectivity, enhanced diagnostic capabilities, and clinician-friendly programming tools is creating differentiation across healthcare providers seeking more personalized treatment pathways. At the same time, the growing importance of clinical evidence, physician training, and integration with broader cardiac care workflows is reinforcing competition around comprehensive therapeutic value, encouraging sustained investment in technologies that support both implantation outcomes and ongoing patient monitoring.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Medtronic plc (Ireland) | |||||||
| Abbott Laboratories (United States) | |||||||
| Boston Scientific Corporation (United States) | |||||||
| Biotronik SE & Co. KG (Germany) | |||||||
| MicroPort Scientific Corporation (China) | |||||||
| LivaNova PLC (United Kingdom) | |||||||
| Lepu Medical Technology (China) | |||||||
| Osypka AG (Germany) |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| BIOTRONIK | Sep-25 | BIOTRONIK commercialized the Amvia Sky HF-T QP pacemaker and CRT-P in Canada, highlighted by the first clinical implant at the Centre Hospitalier de l’Université de Montréal. The triple-chamber system integrates patient-centered design to streamline workflows and deliver advanced therapeutic capabilities. |
| Teleflex Incorporated | Jul-25 | Teleflex completed its strategic acquisition of BIOTRONIK’s Vascular Intervention business for EUR 760 million, broadening its interventional cardiology footprint and strengthening its market positioning within the broader cardiovascular medical device ecosystem. |
| EBR Systems | Apr-25 | EBR Systems secured FDA approval for the leadless WiSE CRT system for heart failure treatment. The innovative system delivers left ventricular endocardial pacing without conventional leads, providing a less invasive and more physiological pacing option for patients requiring heart failure management. |
| Teleflex Incorporated | Feb-25 | Teleflex Incorporated entered into a definitive agreement to acquire substantially all of the Vascular Intervention business of BIOTRONIK for an estimated cash payment of approximately EUR 760 million, translating to USD 892.15 million, significantly expanding its strategic footprint in the interventional cardiology sector. |
| Abbott | Feb-20 | Abbott secured CE Mark approval for the new Gallant implantable cardioverter defibrillator and cardiac resynchronization therapy defibrillator devices. The platform incorporates smartphone connectivity and connected applications to facilitate advanced remote patient monitoring and engagement across the European market. |
| BIOTRONIK | Mar-19 | BIOTRONIK introduced the European market release of its compact ICD and CRT-D devices certified for 3 Tesla full-body MRI scans. The portfolio expansion features extended battery lifespans designed to enhance device longevity and strengthen commercial revenue generation within cardiac resynchronization therapies. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Cardiac Resynchronisation Therapy (CRT) Devices Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Indication | Heart Failure with Reduced Ejection Fraction (HFrEF), Left Bundle Branch Block (LBBB), Atrial Fibrillation with Heart Failure, Other Eligible Cardiac Conditions |
| Implantation Approach | Transvenous Implantation, Epicardial Implantation, Hybrid Implantation |
| Reimbursement Model | Public Insurance, Private Insurance, Self-Pay |
Cardiac Resynchronisation Therapy (CRT) Devices Market — Custom TOC
| Custom Chapter | Custom Details |
|---|---|
| Clinical Adoption Pathways |
|
| Reimbursement & Patient Access Landscape |
|
| Untapped Patient Population Assessment |
|
Need a different cut of the data?
Request Custom ResearchHow big is the cardiac resynchronisation therapy devices market?
What is the anticipated CAGR of the cardiac resynchronisation therapy devices industry?
How is the growing prevalence of cardiovascular disease shaping demand for CRT devices?
Why are reimbursement policies important for the CRT devices market?
Why do CRT-defibrillators dominate the CRT devices market?
Why are CRT-pacemakers the fastest-growing product segment in the CRT devices market?
Why does North America lead the CRT devices market?
What is driving CRT device growth in Asia Pacific?
Who are the major participants shaping the cardiac resynchronisation therapy devices landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source | Reference |
|---|---|
| World Health Organization (WHO) | www.who.int |
| U.S. Food & Drug Administration (FDA) | www.fda.gov |
| European Medicines Agency (EMA) | www.ema.europa.eu |
| Centers for Disease Control and Prevention (CDC) | www.cdc.gov |
| National Institutes of Health (NIH) | www.nih.gov |
| National Center for Biotechnology Information (NCBI) | www.ncbi.nlm.nih.gov |
| PubMed | pubmed.ncbi.nlm.nih.gov |
| ClinicalTrials.gov | clinicaltrials.gov |
| International Organization for Standardization (ISO) | www.iso.org |
| ASTM International | www.astm.org |
| Advanced Medical Technology Association (AdvaMed) | www.advamed.org |
| Medical Device Innovation Consortium (MDIC) | mdic.org |
| Biotechnology Innovation Organization (BIO) | www.bio.org |
| International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) | www.ifpma.org |
| U.S. Pharmacopeia (USP) | www.usp.org |
| European Directorate for the Quality of Medicines & HealthCare (EDQM) | www.edqm.eu |
| World Organisation for Animal Health (WOAH) | www.woah.org |
| American Hospital Association (AHA) | www.aha.org |
| OECD Health | www.oecd.org/health |
| World Bank Data | data.worldbank.org |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization